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Abstract
Reversible post-translational protein modifications such as SUMOylation add complexity to cardiac transcriptional
regulation. The homeodomain transcription factor Nkx2-5/Csx is essential for heart specification and morphogenesis. It has
been previously suggested that SUMOylation of lysine 51 (K51) of Nkx2-5 is essential for its DNA binding and transcriptional
activation. Here, we confirm that SUMOylation strongly enhances Nkx2-5 transcriptional activity and that residue K51 of
Nkx2-5 is a SUMOylation target. However, in a range of cultured cell lines we find that a point mutation of K51 to arginine
(K51R) does not affect Nkx2-5 activity or DNA binding, suggesting the existence of additional Nkx2-5 SUMOylated residues.
Using biochemical assays, we demonstrate that Nkx2-5 is SUMOylated on at least one additional site, and this is the
predominant site in cardiac cells. The second site is either non-canonical or a ‘‘shifting’’ site, as mutation of predicted
consensus sites and indeed every individual lysine in the context of the K51R mutation failed to impair Nkx2-5
transcriptional synergism with SUMO, or its nuclear localization and DNA binding. We also observe SUMOylation of Nkx2-5
cofactors, which may be critical to Nkx2-5 regulation. Our data reveal highly complex regulatory mechanisms driven by
SUMOylation to modulate Nkx2-5 activity.
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Introduction
Post-translation modifications of transcriptional factors are
required for strict spatial and temporal regulation of gene
expression. Modifications such as phosphorylation, methylation
and acetylation have long been established as essential regulators
of signal transduction and other cellular processes. More recently,
members of the Small Ubiquitin-related MOdifier (SUMO) family
of proteins have been shown to play important roles in eukaryotic
gene regulation [1]. SUMO is an 11-kDa polypeptide structurally
related to ubiquitin, that can be covalently conjugated to lysine
residues within target proteins at a consensus yKXE site [where y
is a large hydrophobic aminoacid and K is the site of SUMO
conjugation [2]]. This modification is driven by an enzymatic
cascade similar to ubiquitylation in structure but divergent with
regards to its components and biological functions. While
ubiquitylation has traditionally been associated with protein
degradation, modifications by SUMO have been shown to affect
protein-protein interactions, sub-nuclear localization and genome
integrity in a variety of experimental models [3]. In the majority of
cases, SUMOylation of transcriptional factors leads to transcrip-
tional repression. This occurs via alteration of sub-nuclear
localization [4], or by interaction with transcription co-repressors
including HDACs, as shown for Elk-1, GATA1, GATA2 and SRF
[5,6,7,8]. Despite its usual repressive role, modifications by
SUMO can also direct transcriptional activation, as is the case
for HIF1-a, HSF1, NFAT-1 and p53 [9]. Interestingly, SUMOy-
lation can activate transcription of muscle and cardiac-specific
transcription factors, such as GATA4, myocardin and ERK5
[10,11,12]. In several instances, lysines targeted by SUMO are
also sites for other post-translational modifications, such as
acetylation, methylation and ubiquitylation. Thus, the nature of
the modifier can lead to distinct functional outcomes, including
changes in protein stability, sub-nuclear localization or transcrip-
tional activity [1].
Nkx2-5/Csx is a homeobox transcription factor from the NK
class expressed in cardiac progenitor cells and cardiomyocytes
during embryonic development in all vertebrates. In the heart, this
factor is essential for heart specification, spatial definition of
chamber myocardium and formation and maintenance of
elements of the conduction system [13,14,15,16]. The Nkx2-5
gene was initially identified by its high degree of homology to the
Drosophila tinman gene, which is responsible for the formation of the
dorsal vessel, the fly analogue of the heart [17]. In vertebrates,
targeted deletion of Nkx2-5 in embryos leads to severe impairment
of cardiac morphogenesis and defects in ventricular and outflow
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loss of the repressive function of Nkx2-5 in regulating early
proliferation of the secondary heart field and the Bmp2/Smad
inductive pathway [19]. Highlighting its importance in cardiogen-
esis, more than 32 mutations in NKX2-5 have been identified in
patients with congenital heart disease, thus making this gene one of
the most common single causes of such birth defects [20]. Recent
data in mice have demonstrated that the wide range of clinical
manifestations in Nkx2-5 mutants occurs through pleiotropic
effects caused by genetic modifiers in the genome [21].
Here we show that over-expression of SUMO stimulates Nkx2-
5 transcription up to 250-fold, but in disagreement with previous
publications [22,23], Nkx2-5 is SUMOylated in vitro in at least two
dominant sites. One SUMOylation site corresponds to the
previously identified K51 (21) while the other remains unidenti-
fied, occurring at a non-canonical or ‘‘shifting’’ site. We provide
evidence that SUMOylation of Nkx2-5 and its cofactors
synergistically activates transcription of specific promoters and
potentially influences other post-translational modifications. Mu-
tagenesis of K51 alone, or in the context of mutations in all other
lysines individually, did not alter Nkx2-5 DNA binding, stability or
nuclear localization.
Methods
Cell culture and transient transfections
HEK293T and COS-7 cell lines were obtained from ATCC
(Rockville, MD). Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM-GIBCO) supplemented with 10% (vol/vol) fetal
bovine serum (GIBCO), maintained in a humidified 10% CO2
incubator at 37uC. Cells were seeded into 6-well plates to reach
70% confluence and were transiently transfected using Lipofecta-
mine/Plus reagents (Invitrogen) as previously described [24]. For 6
well plates we used 0.25 mg of test plasmids, 0.2 mg of promoter
construct (pANFLuc, encoding the atrial natriuretic factor reporter
element; Gja5Luc, containing the 21190/+121 promoter region of
mouse Cx40 gene [24], Isl1Luc, containing 1.5 Kb upstream of the
transcription start site of Islet1; Pitx2Luc, containing 2.5 Kb
upstream of the transcription start site of Pitx2 and SM22aLuc,
with approximately 5 kb upstream of the transcription start site of
smooth muscle SM22). Test plasmids were: pcDNA3-Nkx2-5,
pcDNA3-Nkx2-5 I183P (Nkx2-5 mut), pFLAG-Nkx2-5, pMT3-
HA-SUMO-1, pEM-Gata4, pEF FLAG-Tbx5, pcDNA3-Tbx20a
[24,25]. All pcDNA3-Nkx2-5 lysine to arginine mutants were
generated by site directed mutagenesis (QuickChange Site-
Mutagenesis Kit, Stratagene). SUMO-1DGG/Nkx2-5 fusion
clones were obtained via the Gateway strategy (Invitrogen) and
inserted in pcDNA3.2/V5-DEST (Invitrogen). pCGN-Nkx2-5
and pCGN-Nkx2-5K51R were described elsewhere (21). Cells
were harvested after 48 hours. Transfections were performed in
triplicates in at least 2 independent experiments. Expression
patterns of wildtype and mutant Nkx2-5 in transfected cells were
assessed using immunofluorescence microscopy and western
blotting as previously described [25].
Expression analysis
In situ hybridization methods were as described [25,26]. Probes
were generated by PCR, cloned into pGEMTeasy (Promega). To
obtain sense and antisense transcripts, reactions were performed
using T7 or SP6 RNA Polymerase (Roche). For qPCR, total RNA
was isolated from tissues and cell lines using Trizol (Invitrogen) or
RNAqueous 4PCR (Ambion). 1 mg of total RNA was treated with
RQ1 DNase (Promega) and assayed for RT-PCR as previously
described [24]. Realtime PCR was performed using specific mouse
TaqMan Gene Expression Assay probes and assayed using the
LightCycler 480 Real-Time PCR System (Roche).
Co-immunoprecipitation and western blotting analysis
Lysates were prepared by harvesting transiently transfected
HEK293T, COS-7 or HL-1 cells in Reporter lysis buffer, Passive
lysis buffer (Promega) or CO-IP lysis buffer (50 mM Tris pH7.5;
15 mM EGTA; 100 mM NaCl; 0.1% Triton-X 100). For
immunoprecipitation assays, cell lysates were incubated with
anti-Flag M2 affinity gel (Sigma-Aldrich) or anti Nkx2-5 antibody
(St. Cruz)/protein A sepharose (GE Healthcare) in CO-IP lysis
buffer supplemented with 50 mM NEM (Sigma-Aldrich) to
prevent de-SUMOylation, incubated at 4uC for 2 hours, and
washed 3 times in PBS (with protease inhibitors and NEM).
FLAG-tagged proteins were eluted by addition of 150 ng/ml
36FLAG peptide (Sigma-Aldrich). For de-phosphorylation assays,
cellular extracts were incubated with lPPA (New England
Biolabs). Soluble extracts were subjected to immunoblotting with
rabbit polyclonal anti-Nkx2-5 antibody (1:600 dilution, Santa
Cruz Biotechnology), mouse monoclonal anti-Nkx2-5 (1:200
dilution, Abnova Corp.), mouse monoclonal anti-SUMO-1
(1:1000 dilution, Developmental Studies Hybridoma Bank), mouse
monoclonal anti-a-tubulin (1:600 dilution, St. Cruz Biotechnolo-
gy) and anti-HA antibodies (1:4000 dilution, Sigma-Aldrich), anti-
rabbit or anti-mouse IgG HRP-conjugated secondary antibodies
(1:4000 dilution, Amersham Biosciences), anti-rabbit Alexa Fluor
750 (1:8000 dilution, Invitrogen) and anti-mouse Alexa Fluor 680
(1:20000 dilution, Invitrogen). Membranes were developed using
ECL-Plus detection reagent (Amersham Pharmacia) followed by
X-ray film exposure or analysis using Odyssey Infrared Imaging
System (LICOR Biosciences) [27].
Immunohistochemistry
Wild type 9.5dpc embryos were fixed in 4% PFA, mounted in
paraffin and sectioned. Immunohistochemistry was performed
using rabbit polyclonal anti-Nkx2-5 antibody (1:100 dilution, St.
Cruz Biotechnology), mouse monoclonal anti-SUMO-1 (1:100
Developmental Studies Hybridoma Bank), and anti-mouse IgG
HRP-conjugated secondary antibody (1:250 dilution, Amersham
Biosciences), as previously described [27]. Staining was developed
with DAB substrate (Vector Laboratories). Slides were mounted
with VectaMount (Vector Laboratories) and photographed using a
Zeiss Axiolab microscope at 206magnification.
Immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde, washed
in PBS, permeabilized with 0.1% Triton-X 100 and blocked with
10% goat serum. Cells were then incubated with primary rabbit
polyclonal anti-Nkx2-5 antibody (1:200 dilution, Santa Cruz
Biotechnology), rabbit polyclonal anti-SUMO-1 (1:100 dilution,
Zymed Laboratories), and Alexa 555 anti-rabbit secondary
antibody (1:200 dilution, Invitrogen), and were mounted in
Vectashield/DAPI (Vector Laboratories). Slides were examined
with a Zeiss Axiolab fluorescence microscope at 406 magnifica-
tion.
Electrophoretic Mobility Shift Assay (EMSA)
In vitro translated [S
35]-labelled Nkx2-5 (TNT Quick Coupled
System, Promega) or nuclear extracts from transfected HEK293T
or HeLa cells were mixed with binding buffer (25 mM Hepes
pH 7.4; 75 mM NaCl; 1 mM MgCl2; 0.2 mM EDTA; 0.1% v/v
NP-40; 1 mM DTT; 10 ng BSA; 200 ng poly dI/dC) and
incubated for 10 min at room temperature. Annealed oligonucle-
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32P] ATP and T4 polynucle-
otide kinase (New England Biolabs). 50000 cpm were added to
each sample and incubated at room temperature for 20 min. 10 ml
of the mixture was separated on a 5% PAGE gel using 0.56TBE
or 16 Tris-Glycine buffer, dried and subjected to autoradiogra-
phy.
Results
SUMOylation machinery is expressed in the heart and
potentially targets cardiac transcriptional factors
SUMOylation of proteins is an essential process in cellular
homeostasis. Ablation of key components of this pathway can lead
to lethality and/or severe impairment of cellular functions in mice
[9]. In an attempt to understand the role SUMOylation plays in
cardiogenesis, we mapped expression of SUMO pathway
components during heart morphogenesis. Whole-mount in situ
hybridization experiments were performed in mouse embryos
from 8.5 to 11.5 days post-coitum (dpc) (Figure 1A). mRNA
transcripts for genes encoding SUMO-1, SUMO-2, Uba2, Pias1
and Pias2 were widespread although showed abundant enhance-
ment at sites of intensive morphogenetic activity, such as the
branchial arches and limb buds. The specificity of detection was
demonstrated by the lack of signal using sense control probes
(Figure S1). In cardiac development, enrichment of SUMO-1 and
SUMO-2 mRNA was evident at the outer curvature of the
developing heart tube, regions corresponding to the trabecular
(working) chamber myocardium which specifically expresses a
number of genes including that for atrial natriuretic factor (Nppa)
(Figure 1B) [28]. This suggests a concomitant increase of
components of the SUMOylation pathway in cardiac chamber
regions undergoing proliferative growth and differentiation.
Consistent with SUMO expression in the heart, we had
previously isolated a full length Xenopus SUMO-1 cDNA in a
Figure 1. SUMOylation and cardiac embryonic development. (A) In situ hybridization analyses of SUMO pathway components at different
developmental stages in the mouse (from 8.0 to 11.5 dpc, with ventral view at 8.0 dpc, and lateral view 9.5–11.5 dpc). Transcripts were seen in most
embryonic regions, but enhanced expression could be noted in sites of extensive morphogenesis, such as the neural folds (8.0 dpc), branchial arches
and limb buds (9.5 to 11.5 dpc). Arrows indicate cardiogenic regions at 8.0 dpc. (B) In situ hybridization revealed cardiac expression of SUMO-1 and
SUMO-2, with stronger expression in the outer curvature, as demonstrated by Nppa transcripts. la – left atria; lv – left ventricle; rv – right ventricle; ra –
right atria; oft – outflow tract.
doi:10.1371/journal.pone.0024812.g001
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library, using full length Xenopus Nkx2-5 as a bait [29]. To map the
interaction site, we created a series of amino- and carboxy-
terminal deletions of Xenopus Nkx2-5, and tested for interaction
with full length SUMO-1 in the Y2H assay (Figure S2). All tested
deletions interacted with SUMO-1, suggesting that the protein
contains several interaction sites in yeast. In contrast, the related
homeodomain protein Nkx2-2 from Xenopus did not to interact
with SUMO-1 in this assay. However, we failed to demonstrate
direct protein-protein interaction between SUMO-1 and Xenopus
Nkx2-5 using an in vitro glutathione S-transferase (GST) pull-down
assay, perhaps because the interaction was weak out of its correct
context, and/or that GAL4-SUMO-1 in fact became covalently
linked to Nkx2-5 in the Y2H assay.
Nkx2-5 is SUMOylated at lysine 51 and another non-
canonical site
To obtain stronger evidence for involvement of SUMOylation
in cardiac transcriptional regulation, we turned to a cell culture
system using the mouse homologue of Nkx2-5. HEK293T cells
were transiently co-transfected with Nkx2-5 and/or HA-tagged
SUMO-1. In the presence of SUMO-1, we were able to detect the
appearance of two extra bands that reacted with both Nkx2-5 and
HA-specific antibodies using western blotting, indicating that
Nkx2-5 is indeed SUMOylated in this system (Figure 2A, left
panels). These experiments were performed in the presence of N-
ethylmaleimide (NEM), an inhibitor of SUMO-proteases, which
cleaves off the SUMO moiety from modified proteins. The same
bands were also detectable with an independent Nkx2-5 antibody
(data not shown). Results were confirmed by immunoprecipitation
(IP) of extracts from transfected cells with Nkx2-5 antibody, with
subsequent western blotting using the HA antibody. The Nkx2-5
antibody also specifically precipitated the same two slowly
migrating SUMOylated bands (Figure 2A, right panel). This
pattern was also obtained in HeLa and COS-7 cell lines (Figure
S3A, B), suggesting that the modification is cell-type independent.
No bands of higher molecular weight (MW) were detected on these
blots, indicating that either Nkx2-5 is modified at independent and
exclusive sites, or that the levels of doubly SUMOylated Nkx2-5
fell below the level of reliable detection using this assay.
In order to confirm that the SUMO modification was present
on native Nkx2-5 in cardiac cells we performed similar IP
experiments in NEM-treated extracts from the atrial muscle cell
line HL-1, which beats spontaneously in culture [33] and expresses
endogenous Nkx2-5 and a host of other cardiac transcription
factors important for heart development (data not shown). We
were able to detect 2 endogenous Nkx2-5-SUMOylated bands
running at the same MW as those detected in transfection studies
that, as before, represented a minor proportion of the total Nkx2-5
pool. In this case there was a strong expression bias favouring the
upper, more slowly-migrating species. These bands were detected
after western blotting with antibodies for both Nkx2-5 and
SUMO-1. At least two additional SUMO species were detected in
the western blot with SUMO-1 antibody (Figure 2B), likely
representing SUMOylated Nkx2-5 cofactors, or in the case of the
larger band, a poly-SUMOylated species. A high MW Nkx2-5 or
Nkx2-5-interacting species containing SUMO was also detected
without NEM and diminished with NEM. The nature of these
other complexes remains to be determined.
The presence of mono-SUMOylated bands migrating in
different positions has been described for other proteins and
may be due to the branched nature of modified proteins, or to
additional post-translational modifications such as phosphoryla-
tion or acetylation [30,31]. Previous studies have shown that
Nkx2-5 can be phosphorylated at serine163 by casein kinase II
[32] leading to a more slowly migrating band on PAGE (Figure 2C,
lower right panel). To test whether phosphorylation of Nkx2-5
could lead to changes in SUMOylation pattern, extracts of
transfected cells prepared in the presence of NEM were treated
with l Phosphatase (lPPA). This led to the disappearance of the
more slowly migrating band of the main Nkx2-5 doublet
(Figure 2C, lower left panel). However, no change in migration
of the Nkx2-5/SUMO-1 bands was observed (Figure 2C, upper
panels), indicating that the SUMOylation pattern was unrelated to
the phosphorylation status of Nkx2-5. However, it remains
possible that the phosphorylated form of Nkx2-5 cannot be
SUMOylated in vivo.
The western blotting analysis performed thus far indicated that
only a small portion of Nkx2-5 protein present in extracts from
transfected cells was SUMOylated, even when extracts were
prepared in the presence of the SUMO-protease inhibitor NEM.
This is likely due to the highly transient nature of this modification
and/or that only Nkx2-5 protein participating in active transcrip-
tional complexes is SUMOylated. Electrophoretic mobility shift
assay (EMSA) performed on NEM-treated extracts from HeLa
cells transfected with Nkx2-5 plasmid, with or without the HA-
SUMO plasmid, we were able to demonstrate that the small
proportion of the total Nkx2-5 protein pool that was SUMOylated
Figure 2. Nkx2-5 is SUMOylated in HEK293T and cardiac HL-1 cells. (A) Transiently transfected HEK293T cells expressing Nkx2-5 and HA-
SUMO-1 proteins alone or simultaneously. Addition of HA-SUMO-1 led to the appearance of two extra bands by western blot, specific for both HA
and Nkx2-5 antibodies. (B) Co-IP experiments performed in cardiac HL-1 cells with Nkx2-5 antibody display a similar pattern of SUMOylation
(arrowheads) but with increased detection of the slow-migrating SUMOylated Nkx2-5 band. Stars (*) indicate SUMOylated proteins co-precipitated
with Nkx2-5 antibodies. (C) Incubation of cellular extracts with lPPA caused the disappearance of the slower migrating band detected by Nkx2-5
antibodies (lower left panel), while no change in the pattern of migration of the Nkx2-5/SUMO-1 co-stained bands was observed (upper left panel).
doi:10.1371/journal.pone.0024812.g002
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minor supershifted bands in the presence of increasing concen-
trations of HA antibody (Figure S3C).
To identify the SUMOylation sites present in Nkx2-5 we first
used a bioinformatics approach (Sumoplot
TM – www.abgent.com.
cn/doc/sumoplot). Two sites, (K51 [aa50–54; FKPE] and K103
[aa102–105; AKDP]) in the amino-terminal region of the mouse
protein were identified as potential SUMOylation sites, although
only K51 had the signature sequence yKXE (Figure 3A and
Figure S4). K51 showed an almost perfect conservation from
human to fish while K103 displayed higher evolutionary
divergence. Our analysis further revealed two less-conserved
SUMOylation sites in the amino-terminus at residues 108–111
(K109; KKEL; Fig. 3A) and 122–125 (K123; DKAE; Figure S4).
In order to increase the confidence of this prediction we performed
an analysis using another algorithm, SUMOsp2.0 [34]. This
confirmed K51 as a major site and also identified K109 when less
stringent parameters were applied.
To characterize which residues of Nkx2-5 were actually modified
in cells, the core lysines K51, K103 and K109 were changed into
arginine by site-directed mutagenesis. K-to-R mutations have been
previously shown to abolish SUMOylation. Nkx2-5 K51R, K103R
and K109R mutant constructs were transfected in HEK293T cells
and SUMOylation profiles assessed by western blotting with
Figure 3. Identification of putative Nkx2-5 SUMOylation sites. (A) Nkx2-5 sequences from fish to humans were analyzed bioinformatically
and canonical conserved sites were identified at the amino-terminal region of the protein. (B–C) HEK293T cells were co-transfected with HA-SUMO-1
and single putative SUMOylation site mutants (K51R, K103R, K109R or the triple mutant 3K–R), and the band pattern was assessed by western blot
with antibodies for HA and Nkx2-5. Transfection of K51R caused the disappearance of one previously detected SUMOylated band, indicating that K51
is a site for SUMO modification. All other mutants had identical SUMOylation pattern to the wild-type protein, suggesting that those were not
SUMOylated sites. TND, TN domain; HD, homeodomain; NKD, NK2 specific domain; YRD, tyrosine-rich domain.
doi:10.1371/journal.pone.0024812.g003
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the disappearance of the faster migrating band (Figure 3B),
indicating that Nkx2-5 is SUMOylated at this site. Dephosphory-
lation of Nkx2-5 with lPPA did not affect the gel pattern of K51R
(Figure 3C). The same results were obtained in HeLa cells (data not
shown). However, K103 and K109 mutants had identical
SUMOylation patterns to the wild-type protein (Figures 3B). The
persistence of a slower migrating band with mutation of K103 and
K109 implies either the presence of an additional site for
SUMOylation in Nkx2-5, or perhaps the ability of both of the
closely spaced K103 and K109 sites to accept a SUMO
modification depending on which is dominant and available (a
‘‘switching’’ site). In order to test this hypothesis, a triple mutant
construct (3K–R) was generated (Figure 3C). However, the upper
band was still detectable, confirming the presence of an unidentified
non-consensus SUMOylation site in Nkx2-5.
SUMOylation of Nkx2-5 leads to transcription activation
in a promoter-specific manner
The presence of components of the SUMO pathway in the
heart coupled to reports that SUMOylation is capable of
regulating the activity of numerous transcription factors [35,36]
led us to test whether overexpression of SUMO-1 could affect
Nkx2-5 activity on known cardiac target genes in HEK293T
cells. As previously seen by our group and others, in such in vitro
assays full length Nkx2-5 alone is normally a weak activator
(around 4–5 fold) of the Nppa promoter, which carries an Nkx2-5
binding element (NKE) [24,25,37]. SUMO-1 showed an increase
in background (Nkx2-5-independent) activity, but co-transfection
of Nkx2-5 and SUMO-1 led to a robust increase in activation of
the Nppa promoter. Stimulation was ,50-fold compared with
Nkx2-5 without SUMO-1, or ,6-fold compared to SUMO-1
only (Figure 4A). This effect was dose dependent. Stimulation was
also observed when CV-1 and COS-7 cells were used (Figure
S5A, B).
The SUMO-1-mediated synergism observed for Nkx2-5 was
specific, since it was not seen for other cardiac transcription factors
that are capable of regulating the Nppa promoter region [24,25]
(Figure 4B). In order to test whether SUMO-mediated synergy
requires Nkx2-5 binding to its DNA target site, we tested the
ability of a functionally impaired mutant Nkx2-5, in which the
isoleucine residue at position 183 was changed to proline (Nkx2-
5mut), thus disrupting the helix-turn-helix fold of the homeodo-
main [38], to activate the Nppa promoter upon SUMOylation.
Addition of Nkx2-5mut completely abolished SUMO-mediated
activation, confirming that direct binding of Nkx2-5 to the Nppa
promoter or to essential cofactors that interact directly with the
homeodomain fold, is essential for SUMO-1-mediated synergy
(Figure 4C). The Drosophila tinman protein, an Nkx2-5 orthologue,
also displayed SUMO-1-dependent transcriptional activation,
implying an ancient role for this modification in evolution of the
cardiac regulatory network (Figure 4D). This activation occurred
despite the lack of a homologous K51 site in the tinman amino-
terminus, suggesting the presence of alternative sites for SUMOy-
lation in tinman or the recruitment of other SUMOylated co-
activators to transcription initiation sites.
Figure 4. SUMOylation leads to synergistic activation of a cardiac-specific promoter by Nkx2-5. (A) HEK293T cells were transiently
transfected with Nkx2-5, HA-SUMO-1 and the Nppa promoter. Activity is expressed as the fold-increase in luciferase expression. (B) No significant
SUMO-1-mediated activation of the Nppa promoter was observed for other cardiac transcriptions factors (Tbx20a and GATA4/5), indicating that this
effect was specific to Nkx2-5. (C) HEK293T were transiently transfected with wildtype Nkx2-5 or with a homeodomain point mutant that decreases
DNA binding affinity. Addition of mutant protein abolishes SUMO-mediated activation. (D) The Drosophila homolog of Nkx2-5 gene, tinman, also
displays SUMO-1-dependent transcriptional activity.
doi:10.1371/journal.pone.0024812.g004
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induced activation of other muscle and cardiac-specific promoters.
SUMO-1 activity was promoter–specific, positively regulating
SM22a and Isl1, but not significantly affecting the Pitx2 promoter
(Figure 5A–C). In contrast, SUMO-1 appeared to slightly repress
Nkx2-5-dependent activation of the Gja5 promoter. Isl1 is a
marker of cardiac progenitor cells in the embryo and an important
gene for deployment of second heart field (SHF) progenitors to the
growing heart [19,39], and our transfection data provide in vitro
evidence that SUMOylation of Nkx2-5 and/or its cofactors
directly regulates Isl1 promoter activity. Our whole-mount in situ
hybridization experiments (Figure 1A) hinted that there was a
spatial correlation between expression of SUMOylation pathway
components and both the myocardium and its progenitor fields. In
order to confirm this relationship, we dissected 8.0–8.5 dpc
embryos and isolated linear/looping heart tubes, corresponding
predominantly to descendants of the first heart field (FHF), and
from adjacent trunk regions (second heart field enriched region –
eSHF). Using qPCR (Figure 5D), we were able to demonstrate the
presence of all analysed SUMO pathway mRNAs (encoding Isl1,
SUMO-1, SUMO-2, Pias1, Pias2 and Pias4) in both heart and
SHF. This was further confirmed by immunohistochemistry in
9.5dpc embryos, where Nkx2-5 and SUMO-1 showed co-
localization in known SHF-derived embryonic regions - dorsal
pericardial (splanchnic) and branchial arch (lateral) mesoderm
(lm), and the outflow tract myocardium (oft) (Figure 5E). Together,
this data suggests a role for SUMOylation in SHF transcriptional
regulation.
Mutagenesis of K51 SUMOylation site does not change
nuclear localization and DNA binding affinity
Modifications by SUMOylation can lead to a broad range of
effects in target proteins, including altered sub-nuclear localiza-
tion, DNA affinity or interaction with other proteins [9,40].
Mutagenesis of K51 or a combination of all 3 putative
SUMOylation sites K51/103/109 (3K–R; see above) had no
significant effect on Nkx2-5 SUMOylation-dependent transcrip-
tional activity of the Nppa promoter (Figure 6A). In addition,
mutation of K51 did not affect nuclear localization of co-
overexpressed Nkx2-5 with SUMO-1 (Figure 6B). This was also
observed when other lysines were mutated, or even for 3K–R
(Figure 6B). To determine whether any of the K-to-R mutations in
Nkx2-5 altered its DNA binding affinity, K51 and 3K–R were
compared to wildtype Nkx2-5 using EMSA. No significant
differences were detected between wildtype and mutant proteins
with or without addition of SUMO-1 in either HEK293T or HeLa
cell extracts (Figure 6C and data not shown).
In an attempt to discover the second putative SUMOylation
site, we changed every lysine in Nkx2-5 into arginine
individually, in conjunction with K51. All double mutants still
displayed the upper migrating band (Figure 7A) and were able to
activate the Nppa promoter at similar or greater levels when
Figure 5. Synergism of SUMOylation with Nkx2-5 is promoter-specific. (A–C) SUMO-1 and Nkx2-5 failed to activate the cardiac promoters
Gja5 (A) and Pitx2 (B) but could weakly activate Isl1 (B) and SM22 (C) promoters in HEK293T cells. (D) qPCR from First Heart Field (FHF) and trunk
region enriched for Second Heart Field progenitors (eSHF) show presence of several SUMO components in both regions analysed. Regions used in
this experimented are represented as red lines on E8.5 mouse embryo diagram (left). The relative levels on both regions were shown by non-
saturated cycling PCR (30 cycles) followed by gel electrophoresis. (E) Immunohistochemistry of E9.5 embryos sections show Sumo-1 and Sumo-2
widely expressed and this pattern overlaps with Nkx2-5 expressing regions derived from Second Heart Field (SHF), including the outflow tract (oft)
and lateral mesoderm (lm). lm – lateral mesoderm; oft – outflow tract; fg – foregut.
doi:10.1371/journal.pone.0024812.g005
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none of these mutant combinations abolished the second
SUMOylation site of Nkx2-5, or SUMO-stimulated transactiva-
tion. Interestingly, the double mutant K51/191 showed a
significant increase in SUMO-mediated Nkx2-5 activation of
Nppa in HEK293T cells (Figure 7B), suggesting that this residue
is involved in a repressive activity, perhaps involving SUMOyla-
tion on chromatin at undetectable levels, or a distinct
modification or cofactor interaction.
Deletion of the carboxi-terminal region of Nkx2-5 (DC) has
previously been shown to significantly stimulate its transcriptional
activity in vitro, and has led to the hypothesis that in vivo, the amino-
terminal transactivation domain in Nkx2-5 is in some way masked
by the carboxi-terminus or repressed by carboxi-terminal cofactor
interactions [37]. While we also saw a significant stimulation of
trans-activity in Nkx2-5DC, perhaps due to its increased stability,
the SUMO-mediated activation seen with wt Nkx2-5 was
significantly blunted (Figure 7C). This effect seemed independent
of canonical SUMOylation status of Nkx2-5 in its carboxi-
terminus, since the double mutant K51/224R (residue 224 is the
only lysine present at the carboxi-terminal region) still showed
strong SUMO-mediated activation of Nppa (Figure 7B). Our data
suggest that SUMO-dependent activation could be mediated not
so much by SUMOylation of Nkx2-5 itself, but by SUMOylation
of its cofactors. In order to test this more directly, we generated a
chimeric protein that fused SUMO-1 carrying a deleted
deSUMOylation protease site (SUMO-1DGG) to the amino-
terminal region of wild type or K51R Nkx2-5. Covalent linear
attachment of SUMO to its target has been previously shown to
mimic the activity of SUMO conjugation [41,42,43]. Despite
being constitutively SUMOylated, the SUMO-1DGG-Nkx2-5 and
SUMO-1DGG-Nkx2-5K51R constructs were not more active on
the Nppa promoter when compared to transfection of Nkx2-5
alone (Figure 7D). However, both wildtype and K51R chimeric
proteins retained the ability to be strongly augmented after co-
trasfection of SUMO-1 plasmid. This occurred to levels similar to
that of wt Nkx2-5, indicating functional integrity of the fusion
constructs. In total, our results strongly suggest that SUMOylation
of endogenous Nkx2-5 cofactors is a dominant component of
SUMO-stimulated and Nkx2-5-dependent activation of the Nppa
promoter in vitro (Figure 4C). We favour the view that Nkx2-5
activity is tightly regulated by a complex interplay between
SUMOylation and ubiquitylation of both Nkx2-5 and its cofactors,
as previously seen for other essential transcription factors [44].
Discussion
Transcriptional activity during development must be tightly
regulated in order to drive the dynamic changes that result in
organ morphogenesis. This is in part achieved by tissue-specific
transcription factors binding to gene promoter and enhancer
regions, and recruitment of the general transcription machinery
[45]. Transient post-translational modification of transcription
factors allows a higher capacity for rapid changes in activity, and
either binary or graded regulation of transcription. SUMOylation
of proteins involved in transcriptional regulation has now been
recognized as a widely used regulatory step in this process [36].
Here we show that SUMO modifiers are present in the heart and
that enhancing SUMOylation within the cell by transfection of
SUMO-1 plasmid dramatically enhances the activity of the
cardiac transcription factor Nkx2-5, as previously shown for
GATA4 and Myocardin [11,12]. However, our findings suggest
that regulation occurs through a complex mechanism involving
direct SUMOylation and changes in the recruitment of SUMOy-
lated co-activators.
Analysis of the expression pattern of components of the
SUMOylation pathway by in situ hybridization in early mouse
development revealed widespread expression of several compo-
nents, reflecting the essential nature of this modification for
normal cellular function. In contrast to ubiquitylation, the
enzymatic pathway that leads to SUMOylation has a limited
number of components, with only one E2 (Ubc9) and one E1
dimer (Aos1/Uba2) described so far [1,46,47]. In budding yeast,
SUMO, E1 or E2 are required for cell survival, while depletion of
E2 in worms, plants and mice results in embryonic death [1,48,49]
and may also be involved in neurodegerative diseases like
Huntington’s disease (HD), spinocerebellar ataxias (SCA), Ma-
chado–Joseph disease, spinal and bulbar muscular atrophy
(SBMA) and Ab-amyloidogenesis [50]. Expression of SUMO-1,
SUMO-2 and Uba2, and to a lesser extent Pias1/2, were
moderately enriched in the outer curvature of the developing
heart. This region, which differentiates into trabecular working
myocardium, is demarcated by several chamber-specific transcrip-
tion factors and other genes, including Hand1, Cited1, Chisel/Smpx,
Gja5 and Nppa [51]. The gene regulatory network established in
chamber muscle during development is labile and requires
signalling support provided by the endocardial layer [52]. The
inner curvature (non-chamber myocardium) of the heart, in
contrast, expresses Tbx2 and Tbx3, T-box transcription factors
that inhibit chamber specification [53,54]. Expression of cardiac
compartment genes is thus under the strict control of a highly
conserved pathway that includes Nkx2-5, Gata4 and multiple T-
box factors [14,16]. The ability of Nkx2-5 to interact with either
activating (Tbx5 and Tbx20) or repressing (Tbx2, Tbx3) T-box
factors allows specificity of control in different heart domains
[13,27]. Using an unbiased bioinformatic approach, Bauer et al.
have shown that several transcriptional factors with activation/
repression activities share conserved signatures for SUMOylation
[55]. Nkx2-5 can also act as both activator and repressor, although
it remains to be seen whether SUMOylation of Nkx2-5
participates in such changes [13,19,24,56,57].
SUMO-mediated enhancement of Nppa promoter in HEK293T
cells requires Nkx2-5 direct interaction with its target sequence in
the promoter. Mutation of one of the SUMOylation sites located
at K51 did not abolish activity, or change nuclear localization or
DNA binding. For this reason, we believe synergism between
Nkx2-5 and SUMO-1 may be dependent on at least two
SUMOylated residues. The potential second SUMOylation site
Figure 6. Mutagenesis of canonical SUMOylation site (K51) has no effect on Nkx2-5 transcriptional regulation. (A) SUMO-1 stimulates
Nkx2-5-driven reporter activity in a dose-dependent manner, but SUMOylation-defective mutant proteins K51R and 3K-R had no effect on SUMO-
dependent activation. Nkx2-5 and HA-SUMO1 protein levels were detected in cell extracts by western blot, with a-tubulin as loading control. (B)
Immunofluorescence of transiently transfected HEK293T cells show normal nuclear localization of Nkx2-5 mutants K51R, K103R, K109R and 3K–R
when compared to wildtype protein. (C) Nkx2-5 K51R binds to the NKE site with similar affinities to wildtype protein in HEK293T cells using EMSA.
Overexpression of SUMO-1 leads to no detectable change in DNA affinities. S, specific oligonucleotide; NS, non-specific oligonucleotide; SS,
supershift. Note that western blots were performed using extracts for Luciferase readings without NEM, therefore only the non-SUMOylated form of
Nkx2-5 was detected.
doi:10.1371/journal.pone.0024812.g006
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24812Figure 7. Complex regulation of Nkx2-5 activity by SUMOylation. (A–B)MutagenesisofeverylysineinNkx2-5inconjunctionwithK51Rfailedto
change its SUMOylation pattern, as detected by western blot. (B) Most double mutant proteins were not capable of attenuating the activation exerted by
SUMO-1 on Nkx2-5 when the Nppa promoter was used in co-transfection experiments performed in HEK293T cells. The exception was the double mutant
K51/191R mutant that showed strong activation. (C) Deletion of the carboxi-terminal region of Nkx2-5 (DC) impaired SUMO-mediated activation on the
Nppa promoter, despite enhancing Nkx2-5 stability in transient assays (inset). (D) A SUMO-1/Nkx2-5 fusion construct failed to elicit any activation of the
Nppa promoter when compared to the Nkx2-5 WT construct alone, but activation was restored upon addition of exogenous HA-SUMO-1 constructs. Inset:
western blot of extracts used for luciferasereadingsshow presenceof exogenously expressed Nkx-2-5 WT, HA-SUMO-1andSUMO-1/Nkx2-5 fusions(SUMO-
1,Nkx2-5) WT and K51R. Endogenous SUMO-1 and possibly RanGAP1 (*) are also detected.
doi:10.1371/journal.pone.0024812.g007
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extensions of the core SUMOylation site yKXE have been
proposed, including the PDSM (phosphorylation-dependent
SUMOylation motif), the SC (synergy control motif) and the
NDSM (negatively charged amino acid-dependent SUMOylation
motif) [1]. We cannot discard the possibility of other SUMO
modifications occurring at a site with no obvious signature, as seen
for yeast PCNA and others [1,46,58]. We were not able to
significantly affect gene activity upon mutation of all lysines in
Nkx2-5 in the context of K51R. Therefore identification of the
divergent site remains elusive. As noted, it is possible that mutation
of one site leads to modification of another, as a buffering
mechanism to retain protein activity.
SUMO-interacting motifs (SIMs) are transcription factor
domains that have also been implicated in the regulation of
promoter activity, as previously demonstrated for KLF4 and c-
Myb [59,60]. However, SIM motifs work independently of
canonical SUMOylation sites. Recent data shows that a great
part of the physiological outcomes of SUMOylation are mediated
by co-factors that recognize SUMO-modified proteins through
SIM motifs [47]. We demonstrated here that SUMO-1 is capable
of interacting with Xenopus Nkx2-5 through multiple domains of
the protein in yeast two-hybrid assays, but not with the closely
related homeodomain factor Nkx2-2. Furthermore, deletion of
Nkx2-5 C-terminal domain led to the attenuation of SUMO-
mediated activation, independently of residue K224 as a candidate
canonical SUMOylation site. Finally, our assays showed that a
SUMO-1/Nkx2-5 fusion protein was not more active than Nkx2-5
alone, although like wt Nkx2-5 showed enhanced activity after
augmentation of SUMO levels in the whole cell by transfection of
SUMO-1 plasmid. Taken together, these results strongly suggest
that Nkx2-5-associated proteins, potentially SUMOylated them-
selves, may be important for the synergistic activity exerted by
SUMO over Nkx2-5.
Recently, Li et al. showed that the histone acetyl transferase
(HAT) p300 interacts with the N-terminal region of Nkx2-5 [61],
increasing its transcriptional activity. The C-terminal region of
Nkx2-5 acts as a strong negative regulator in vitro [37,62]. Deletion
of this region increases Nkx2-5 activity, stability (this study) and
affinity for p300. One of the most important mechanisms by which
SUMOylation affects transcription is through changes in protein:-
protein binding affinity [1,9,36]. Because the previously identified
K51 SUMOylation site is localized whithin the region required for
p300 interaction, it is tempting to speculate that SUMOylation
might increase Nkx2-5 affinity for p300 or other HAT proteins
and promote strict temporal and spatial regulation of target genes.
In contrast, recruitment of histone deacetylases (HDACs) by
SUMOylation is also a well-established mechanism of transcrip-
tional repression [8,63]. SUMO-regulation of these events may be
important in vivo, although not rate-limiting for transcriptional
assays after over-expression of components in vitro. SUMO-
mediated activation of transcription is likely to be promoter
specific, and indeed Nkx2-5 failed to elicit synergistic responses
with SUMO on a subset of cardiac promoters including Gja5 and
Pitx2 [24,64,65,66,67]. This reinforces the notion that SUMOyla-
tion does not work as an ON/OFF switch as suggested [23], but
modulates transcription in more subtle ways, by responding to
different signalling contexts [3]. This was elegantly shown in rod
photoreceptor development where PIAS3-mediated SUMOyla-
tion of Nr2e3 caused strong transcriptional repression of cone
specific genes, while the recruitment of PIAS3/Crx or PIAS3/
Nr2e3 led to transcriptional activation of rod-specific promoters
[68].
During the course of this project, Wang et al. described
contradictory results on the effect of K51R mutation on Nkx2-5
SUMOylation and activity [23]. These authors described K51 as
the sole SUMOylation site on Nkx2-5, and that mutagenesis of this
site led to complete abolition of SUMO-mediated transcriptional
activation together with total loss of binding to its target DNA
sequences. Despite our best efforts, we could not reproduce this
data, even when using the precise wild type and K51 mutant
expression constructs, as supplied by this group, and identical
HeLa and CV-1 cell stocks. In our hands, both wild type and
mutant proteins were able to bind DNA and transactive the Nppa
reporter in HEK293T and CV1 cells. The difference between the
findings of Wang et al. and those reported here may relate to the
specific methodologies used for expression of plasmids in cultured
cells, or in the stringency of detection of their protein products.
Importantly, however, we show here that Nkx2-5 is multiply
SUMOylated in the cardiac cell line HL-1, and of the two SUMO
species highlighted in in vitro studies, the unidentified slower
migrating band was the predominant one. In our view, the full
SUMOylation status of Nkx2-5 and the meaning of these
modifications in the developing heart remains to be determined.
Recently, although transgenic mice over-expressing Nkx2-5-K51R
were found to be relatively normal, when crossed to mice
heterozygous for a null mutation in Nkx2-5, the majority died
postnatally with reduced cardiomyocyte proliferation, and atrial
and ventricular septal defects [69]. These studies hint at an
important role for SUMOylation of K51 in vivo, although
dysregulation of Nkx2-5 as a result of the transgenic method, as
seen previously for wild type Nkx2-5 [70,71], needs to be
discounted. Reduced SUMOylation of Nkx2-5 point mutations
present in human CHD has also been reported. This finding
suggests a correlation between SUMOylation and the loading of
Nkx2-5 into functional transcriptional complexes, where it could
regulate protein:protein modifications that affect transcription
factor stability and activity, and chromatin modification. For
example, in mice mutant for the de-SUMOylation enzyme
SENP2, the polycomb-related repressor complex PRC1 remains
overactive, leading to repression of cardiac transcription factors
GATA4 and GATA6 [72]. Our findings, combined with those of
others, demonstrate a complex post-translational regulatory
machinery underlying the expression and regulation of several of
the transcription factors that function in the conserved core
regulatory network for cardiogenesis. Further dissection of this
machinery will have significant implications for understanding
cardiac development and CHD.
Supporting Information
Figure S1 Confirmation of the specificity of the in situ probes of
SUMO pathway components. Sp6-derived sense probes display
minimal background at all stages analysed when co-developed
with T7-derived antisense probes in mouse embryos. All
components are widely expressed in developing mouse embryos
as shown in Figure 1.
(TIF)
Figure S2 SUMO-1 interacts with multiple sites in Xenopus
Nkx2-5 but not Nkx2-2. Yeast strain Yn166 (containing a reporter
gene consisting of the Gal4 UAS upstream of the b-galactosidase
coding region) was co-transformed with a yeast expression vector
encoding full length Xenopus SUMO-1 fused to the Gal4 activation
domain, and a second yeast expression vector encoding the Gal4
DNA binding domain fused to the indicated fragments of Xenopus
Nkx2-5. Amino acids contained in each mutant are indicated on
the left. The domain structure of the Nkx2-5 protein is shown
Complex Regulation of Nkx2-5 by SUMOylation
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24812(top). Interaction was assessed by detection of LacZ activity. In
addition, the related Nk2 homeodomain protein Xenopus Nkx2-2
was tested in this assay, but did not interact. In the absence of
Xenopus SUMO-1, none of the constructs were able to activate
transcription of the reporter. TN, TN domain; HD, homeodo-
main; NKD, NK2 specific domain; YRD, tyrosine-rich domain.
(TIF)
Figure S3 The SUMOylation banding pattern is not cell line
specific. (A–B) Western blot analyses demonstrated that both
HeLa (A) and COS-7 (B) cells display two SUMOylated bands
using HA (SUMO-1) and Nkx2-5 antibodies. (C) Electrophoretic
Mobility Shift Assay (EMSA) was performed in transiently
transfected HeLa cells with the addition of 50 mM of NEM (to
prevent cleaveage of the SUMO moiety). This confirms that only a
small portion of the total that Nkx2-5 bound to the Nppa promoter
is modified by SUMO conjugation, as indicated by the appearance
of a supershifted band upon addition of increasing levels of anti-
HA antibodies. The boxed region inset shows HA-SUMO-1
supershifted Nkx2-5 under increased contrast conditions. Note
that most of the Nkx2-5 DNA-bound fraction can be specifically
supershifted with Nkx2-5 antibodies.
(TIF)
Figure S4 Prediction of putative canonical SUMOylation sites
by Sumoplot
TM (www.abgent.com.cn/doc/sumoplot). This algo-
rithm scored K51 and K103 as high probability sites, while K109
and K123 were predicted as low probability sites.
(TIF)
Figure S5 Enhancement of Nkx2-5 transcriptional activity by
SUMO is cell line-independent. (A–B) SUMO-1 synergized with
Nkx2-5 to activate the Nppa promoter in transient transfection of
both CV-1 and COS-7 cells.
(TIF)
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